The practice of active patient involvement in rare disease research using ICT: experiences and lessons from the RUDY JAPAN project.

Dynamic consent Information and communication technology Information technology Patient involvement Patient reported outcome measures Patient-centered research Rare diseases

Journal

Research involvement and engagement
ISSN: 2056-7529
Titre abrégé: Res Involv Engagem
Pays: England
ID NLM: 101708164

Informations de publication

Date de publication:
01 Feb 2021
Historique:
received: 26 06 2020
accepted: 15 01 2021
entrez: 2 2 2021
pubmed: 3 2 2021
medline: 3 2 2021
Statut: epublish

Résumé

The role of patients in medical research is changing, as more emphasis is being placed on patient involvement, and patient reported outcomes are increasingly contributing to clinical decision-making. Information and communication technology provides new opportunities for patients to actively become involved in research. These trends are particularly noticeable in Europe and the US, but less obvious in Japan. The aim of this study was to investigate the practice of active involvement of patients in medical research in Japan by utilizing a digital platform, and to analyze the outcomes to clarify what specific approaches could be put into practice. We developed the RUDY JAPAN system, an ongoing rare disease medical research platform, in collaboration with the Rare and Undiagnosed Diseases Study (RUDY) project in the UK. After 2 years of preparation, RUDY JAPAN was launched in December 2017. Skeletal muscle channelopathies were initially selected as target diseases, and hereditary angioedema was subsequently added. Several approaches for active patient involvement were designed through patient-researcher collaboration, namely the Steering Committee, questionnaire development, dynamic consent, and other communication strategies. We analyzed our practices and experiences focusing on how each approach affected and contributed to the research project. RUDY JAPAN has successfully involved patients in this research project in various ways. While not a part of the initial decision-making phase to launch the project, patients have increasingly been involved since then. A high level of patient involvement was achieved through the Steering Committee, a governance body that has made a major contribution to RUDY JAPAN, and the process of the questionnaire development. The creation of the Patient Network Forum, website and newsletter cultivated dialogue between patients and researchers. The registry itself allowed patient participation through data input and control of data usage through dynamic consent. We believe the initial outcomes demonstrate the feasibility and utility of active patient involvement in Japan. The collaboration realized through RUDY JAPAN was enabled by digital technologies. It allowed busy patients and researchers to find the space to meet and work together for the Steering Committee, questionnaire development and various communication activities. While the practice of active patient involvement in Japan is still in its early stages, this research confirms its viability if the right conditions are in place. (331 words).

Sections du résumé

BACKGROUND BACKGROUND
The role of patients in medical research is changing, as more emphasis is being placed on patient involvement, and patient reported outcomes are increasingly contributing to clinical decision-making. Information and communication technology provides new opportunities for patients to actively become involved in research. These trends are particularly noticeable in Europe and the US, but less obvious in Japan. The aim of this study was to investigate the practice of active involvement of patients in medical research in Japan by utilizing a digital platform, and to analyze the outcomes to clarify what specific approaches could be put into practice.
METHODS METHODS
We developed the RUDY JAPAN system, an ongoing rare disease medical research platform, in collaboration with the Rare and Undiagnosed Diseases Study (RUDY) project in the UK. After 2 years of preparation, RUDY JAPAN was launched in December 2017. Skeletal muscle channelopathies were initially selected as target diseases, and hereditary angioedema was subsequently added. Several approaches for active patient involvement were designed through patient-researcher collaboration, namely the Steering Committee, questionnaire development, dynamic consent, and other communication strategies. We analyzed our practices and experiences focusing on how each approach affected and contributed to the research project.
RESULTS RESULTS
RUDY JAPAN has successfully involved patients in this research project in various ways. While not a part of the initial decision-making phase to launch the project, patients have increasingly been involved since then. A high level of patient involvement was achieved through the Steering Committee, a governance body that has made a major contribution to RUDY JAPAN, and the process of the questionnaire development. The creation of the Patient Network Forum, website and newsletter cultivated dialogue between patients and researchers. The registry itself allowed patient participation through data input and control of data usage through dynamic consent.
CONCLUSIONS CONCLUSIONS
We believe the initial outcomes demonstrate the feasibility and utility of active patient involvement in Japan. The collaboration realized through RUDY JAPAN was enabled by digital technologies. It allowed busy patients and researchers to find the space to meet and work together for the Steering Committee, questionnaire development and various communication activities. While the practice of active patient involvement in Japan is still in its early stages, this research confirms its viability if the right conditions are in place. (331 words).

Identifiants

pubmed: 33526087
doi: 10.1186/s40900-021-00253-6
pii: 10.1186/s40900-021-00253-6
pmc: PMC7852111
doi:

Types de publication

Journal Article

Langues

eng

Pagination

9

Subventions

Organisme : Japan Society for the Promotion of Science
ID : JP15K15167
Organisme : Japan Society for the Promotion of Science
ID : JP17K19812
Organisme : Japan Science and Technology Corporation (JP), RISTEX
ID : JPMJRX18B3
Organisme : Ministry of Health, Labour and Welfare
ID : H29-Nanchitou(Nan)-Ippan-030 and 20FC1036
Organisme : Ministry of Health, Labour and Welfare
ID : H29-Nanchitou(Nan)-Ippan 029 and 20FC1052

Références

Am J Bioeth. 2014;14(6):29-31
pubmed: 24809605
Sleep Med. 2009 May;10(5):556-65
pubmed: 18824408
J Allergy Clin Immunol. 2012 Sep;130(3):692-7
pubmed: 22841766
Med Care. 2015 Jan;53(1):9-17
pubmed: 25494232
BMC Med Ethics. 2016 Aug 24;17(1):51
pubmed: 27553007
Eur J Hum Genet. 2015 Feb;23(2):141-6
pubmed: 24801761
J Gen Intern Med. 2016 Jan;31(1):13-21
pubmed: 26160480
Eur J Neurol. 2012 Nov;19(11):1470-6
pubmed: 22607270
J Rheumatol. 2003 Apr;30(4):877-9
pubmed: 12672220
Sleep. 1991 Dec;14(6):540-5
pubmed: 1798888
Md State Med J. 1965 Feb;14:61-5
pubmed: 14258950
BMC Health Serv Res. 2014 Feb 26;14:89
pubmed: 24568690
Appl Transl Genom. 2012 Dec 1;1:25-29
pubmed: 24772384
Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1703-12
pubmed: 27197911
Muscle Nerve. 2018 Jan 17;:
pubmed: 29342319
Patient. 2015 Aug;8(4):301-9
pubmed: 25300613
Neurology. 2007 Mar 27;68(13):1051-7
pubmed: 17389311
Value Health. 2007 Nov-Dec;10 Suppl 2:S86-93
pubmed: 17995478
Soc Sci Med. 2005 Jun;60(11):2575-84
pubmed: 15814182
Allergy. 2016 Aug;71(8):1203-9
pubmed: 27038109
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Eur J Hum Genet. 2017 Jun;25(7):816-822
pubmed: 28443622
Nat Rev Genet. 2007 Feb;8(2):157-64
pubmed: 17230202
Orphanet J Rare Dis. 2016 Nov 8;11(1):150
pubmed: 27825362
Patient. 2012;5(2):71-4
pubmed: 22439689
J Clin Epidemiol. 1998 Nov;51(11):1037-44
pubmed: 9817121
J Gen Intern Med. 2014 Aug;29 Suppl 3:S739-44
pubmed: 25029976

Auteurs

Nao Hamakawa (N)

Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Atsushi Kogetsu (A)

Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Moeko Isono (M)

Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Chisato Yamasaki (C)

Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Shirou Manabe (S)

Department of Medical Informatics, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Toshihiro Takeda (T)

Department of Medical Informatics, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Kazumasa Iwamoto (K)

Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Tomoya Kubota (T)

Department of Functional Diagnostic Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Joe Barrett (J)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Nathanael Gray (N)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Alison Turner (A)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Harriet Teare (H)

HeLEX Centre, University of Oxford, Oxford, UK.

Yukie Imamura (Y)

HAEJ, Non-profit Patient Organization for Hereditary Angioedema in Japan, Kakogawa, Hyogo, Japan.

Beverley Anne Yamamoto (BA)

HAEJ, Non-profit Patient Organization for Hereditary Angioedema in Japan, Kakogawa, Hyogo, Japan.
HAEi, Non-profit International Patient Organization for Hereditary Angioedema registered in the US, Fairfax City, Virginia, USA.
Graduate School of Human Sciences, Osaka University, Suita, Osaka, Japan.

Jane Kaye (J)

HeLEX Centre, University of Oxford, Oxford, UK.

Michihiro Hide (M)

Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Masanori P Takahashi (MP)

Department of Functional Diagnostic Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Yasushi Matsumura (Y)

Department of Medical Informatics, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Muhammad Kassim Javaid (MK)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Kazuto Kato (K)

Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. kato@eth.med.osaka-u.ac.jp.

Classifications MeSH